Gallen International Breast Cancer Conference because some patients did not have immunohistochemistry for Ki-67.32 We have not found the value of Ki-67 in predicting lymph node metastases; this confirms findings from previous studies.33–35 In addition, the ER, PR, and HER2 expressions were mainly detected by immunohistochemistry, which may bias the results, but the results of immunohistochemistry have been widely used in the treatment option for patients with breast cancer. Here, ESR1 is linked to metastatic malignant neoplasm in the lymph nodes.